Table 1 Baseline characteristics of the participants (n = 676)
Sex n (%) | |
 Females | 185 (27) |
 Males | 491 (73) |
Age groups, years n (%) | |
 18—29 | 81 (12) |
 30—39 | 200 (26) |
 40 – 49 | 200 (26) |
 50—59 | 160 (24) |
 60 +  | 35 (5) |
Age, mean (SD) | 43 (11) |
BMI kg/m2, mean (SD) | 25 (4.8) |
Housing situation past 30 days1 n (%) | |
 Stable | 587 (87) |
 Unstable | 89 (13) |
Highest completed education n (%) | |
 Not finished basic education2 | 34 (5) |
 Finished basic education2 | 310 (46) |
 High school3 | 266 (39) |
  < 3 years of higher education | 51 (8) |
  > 3 years of higher education | 15 (2) |
Current OAT medication n (%) | |
 Methadone | 220 (33) |
 Buprenorphine-based | 322 (48) |
 Naltrexone | 1 (0.2) |
 None | 133 (20) |
Regular substance use4 n (%) | |
 Alcohol | 163 (26) |
 Tobacco | 587 (93) |
 Cannabis | 324 (51) |
 Stimulants | 187 (30) |
 Opioids | 99 (16) |
 Benzodiazepines | 236 (37) |
iSUSI5, mean (SD) | 0.36 (0.23) |
Injected past 12 months6 n (%) | 344 (55) |
Hepatitis B antigen positive n (%) |  < 5 (0.7) |
HIV positive n (%) |  < 5 (0.7) |
Hepatitis C status n (%) | |
 Antibody negative | 56 (8) |
 Antibody positive, RNA negative | 251(37) |
 RNA positive | 310(46) |
 Missing information7 | 59 (9) |
Blood tests mean (SD) | |
 Alanine transaminase U/L | 53 (67) |
 Aspartate transaminase U/L | 49 (49) |
 Thrombocytes 109/L | 246 (80) |
 Estimated glomerular filtration rate ml/min/1,73m2 | 107(26) |
Liver disease risk factors and markers n (%) | |
 HbA1c elevated8 | 14 (2) |
 Low HDL9 | 173 (26) |
 Low thrombocytes10 | 62 (9) |
 Obesity11 ≥ 30 kg/m2 | 104 (15) |
 Liver stiffness12 ≥ 10 kPa | 83 (12) |